RxDoctor Payments Data

Kamlesh Parekh

Internal Medicine · Senatobia, MSNPI 1932126083

Payments from drug & device makers

$2,428in general payments, 2019–2025

Across 82 payments — averaging $29.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$488
  • AstraZeneca$339
  • Novo Nordisk$286
  • Bayer$264
  • Abbott$197
  • Boehringer Ingelheim$190
  • plus $662 from 18 others

What the payments were for

  • Food & beverage$2,428100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,428 in reported general payments places this provider in the 75th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$77,463
Medicare patients
169
Services billed
1,277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol25$21,814
Albuterol Sulfate HfaAlbuterol Sulfate27$996
Atorvastatin Calcium95$572
Potassium Chloride15$431
Amlodipine Besylate88$391
Rosuvastatin Calcium60$368
Losartan Potassium54$348
Metoprolol Succinate38$340
Terazosin Hcl11$340
Hydralazine Hcl22$333
FenofibrateFenofibrate Nanocrystallized13$329
Gabapentin22$307
Fluticasone Propionate18$281
Ezetimibe14$279
Levothyroxine Sodium19$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$339$21,81425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Senatobia

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →